{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:16:05Z","timestamp":1787015765115,"version":"build-2736575974"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":2955,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007207","name":"Toray Industries, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007207","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chronic kidney disease (CKD) is a common progressive and irreversible disease in cats. The efficacy and safety of beraprost sodium (BPS) in cats with CKD have not been evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of BPS in the treatment of cats with CKD, as compared to placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Seventy-four client-owned cats with naturally occurring CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Double-blind, placebo-controlled, multicenter, prospective, randomized trial. The cats received BPS (55 \u03bcg\/cat) or a placebo PO q12 h for 180 days. The primary endpoint was prospectively defined as a change in the serum creatinine (sCr), serum phosphorus-to-calcium ratio or urine specific gravity (USG).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The sCr increased significantly (P = 0.0030) in the placebo group (mean \u00b1 SD: 2.8 \u00b1 0.7 to 3.2 \u00b1 1.3 mg\/dL) but not in the BPS group (2.4 \u00b1 0.7 to 2.5 \u00b1 0.7 mg\/dL). The difference between the groups at day 180 was significant (0.8 mg\/dL, 95% CI: 0.2 to 1.3 mg\/dL, P = 0.0071). The serum phosphorus-to-calcium ratio was significantly (P = 0.0037) increased in the placebo group (0.46 \u00b1 0.10 to 0.52 \u00b1 0.21 mg\/dL) but not in the BPS group (0.50 \u00b1 0.08 to 0.51 \u00b1 0.11 mg\/dL). There was no significant change in the USG in either group. An adverse event judged as being treatment-related included vomiting that occurred in 1 case in the placebo group. No clinically relevant change was observed in the CBC and other blood chemistry tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>Beraprost sodium treatment was well tolerated and safe in cats with CKD. BPS inhibited the reduction in renal filtration function as measured by sCr increase.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.14839","type":"journal-article","created":{"date-parts":[[2017,11,13]],"date-time":"2017-11-13T10:06:39Z","timestamp":1510567599000},"page":"236-248","source":"Crossref","is-referenced-by-count":14,"title":["A Double-blind, Placebo-controlled, Multicenter, Prospective, Randomized Study of Beraprost Sodium Treatment for Cats with Chronic Kidney Disease"],"prefix":"10.1093","volume":"32","author":[{"given":"M.","family":"Takenaka","sequence":"first","affiliation":[{"name":"Animal Clinical Research Foundation , Kurayoshi, Tottori,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Iio","sequence":"additional","affiliation":[{"name":"Toray Industries, Inc. , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sato","sequence":"additional","affiliation":[{"name":"Faculty of Agriculture, Iwate University Department of Veterinary Medicine, , Morioka, Iwate,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Toray Industries, Inc. , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9459-9362","authenticated-orcid":false,"given":"H.","family":"Kurumatani","sequence":"additional","affiliation":[{"name":"Toray Industries, Inc. , Tokyo,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the KT-140 Clinical Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Kurumatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,1]]},"reference":[{"key":"2026020303245037000_jvim14839-bib-0001","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/1098612X16631234","article-title":"ISFM consensus guidelines on the diagnosis and management of feline chronic kidney disease","volume":"18","author":"Sparkes","year":"2016","journal-title":"J Feline Med Surg"},{"key":"2026020303245037000_jvim14839-bib-0002","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/0300985812453176","article-title":"Histomorphometry of feline chronic kidney disease and correlation with markers of renal dysfunction","volume":"50","author":"Chakrabarti","year":"2013","journal-title":"Vet Pathol"},{"key":"2026020303245037000_jvim14839-bib-0003","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2460\/javma.1987.190.09.1196","article-title":"Clinicopathologic findings associated with chronic renal disease in cats: 74 cases (1973\u20131984)","volume":"190","author":"DiBartola","year":"1987","journal-title":"J Am Vet Med Assoc"},{"key":"2026020303245037000_jvim14839-bib-0004","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.rvsc.2009.09.003","article-title":"Comparative study of chronic kidney disease in dogs and cats: induction of myofibroblasts","volume":"88","author":"Yabuki","year":"2010","journal-title":"Res Vet Sci"},{"key":"2026020303245037000_jvim14839-bib-0005","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.tvjl.2014.10.009","article-title":"Renal fibrosis in feline chronic kidney disease: known mediators and mechanisms of injury","volume":"203","author":"Lawson","year":"2015","journal-title":"Vet J"},{"key":"2026020303245037000_jvim14839-bib-0006","first-page":"S74","article-title":"Progressive renal disease: the chronic hypoxia hypothesis","volume":"65","author":"Fine","year":"1998","journal-title":"Kidney Int Suppl"},{"key":"2026020303245037000_jvim14839-bib-0007","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1681\/ASN.2005070757","article-title":"Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure","volume":"17","author":"Nangaku","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2026020303245037000_jvim14839-bib-0008","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3121\/cmr.2015.1282","article-title":"Hypoxia: the force that drives chronic kidney disease","volume":"14","author":"Fu","year":"2016","journal-title":"Clin Med Res"},{"key":"2026020303245037000_jvim14839-bib-0009","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/j.1939-1676.2007.tb03042.x","article-title":"Prognostic factors in cats with chronic kidney disease","volume":"21","author":"King","year":"2007","journal-title":"J Vet Intern Med"},{"key":"2026020303245037000_jvim14839-bib-0010","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/263663a0","article-title":"An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation","volume":"263","author":"Moncada","year":"1976","journal-title":"Nature"},{"key":"2026020303245037000_jvim14839-bib-0011","doi-asserted-by":"crossref","first-page":"F235","DOI":"10.1152\/ajprenal.00454.2004","article-title":"Prostacyclin signaling in the kidney: implications for health and disease","volume":"289","author":"Nasrallah","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026020303245037000_jvim14839-bib-0012","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1161\/01.CIR.0000034733.93020.BC","article-title":"Prostacyclin-deficient mice develop ischemic renal disorders, including nephrosclerosis and renal infarction","volume":"106","author":"Yokoyama","year":"2002","journal-title":"Circulation"},{"key":"2026020303245037000_jvim14839-bib-0013","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S0735-1097(99)00312-5","article-title":"Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension","volume":"34","author":"Nagaya","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"2026020303245037000_jvim14839-bib-0014","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1161\/01.CIR.102.4.426","article-title":"Oral beraprost sodium, a prostaglandin I2 analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group","volume":"102","author":"Lievre","year":"2000","journal-title":"Circulation"},{"key":"2026020303245037000_jvim14839-bib-0015","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/db09-1432","article-title":"The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats","volume":"59","author":"Sato","year":"2010","journal-title":"Diabetes"},{"key":"2026020303245037000_jvim14839-bib-0016","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1046\/j.1523-1755.1998.00881.x","article-title":"Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat","volume":"53","author":"Kushiro","year":"1998","journal-title":"Kidney Int"},{"key":"2026020303245037000_jvim14839-bib-0017","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0014-2999(02)01988-X","article-title":"Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model","volume":"449","author":"Yamada","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"2026020303245037000_jvim14839-bib-0018","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.plefa.2009.03.002","article-title":"Effect of beraprost sodium (BPS) in a new rat partial unilateral ureteral obstruction model","volume":"80","author":"Takenaka","year":"2009","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2026020303245037000_jvim14839-bib-0019","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.ejphar.2013.07.032","article-title":"Beraprost sodium improves survival rates in anti-glomerular basement membrane glomerulonephritis and 5\/6 nephrectomized chronic kidney disease rats","volume":"714","author":"Yamaguchi","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"2026020303245037000_jvim14839-bib-0020","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.prostaglandins.2014.06.001","article-title":"A prostacyclin analog prevents the regression of renal microvascular network by inhibiting mitochondria-dependent apoptosis in the kidney of rat progressive glomerulonephritis","volume":"112","author":"Goto","year":"2014","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"2026020303245037000_jvim14839-bib-0021","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.4238\/2014.June.9.1","article-title":"Effects of beraprost sodium on renal function and inflammatory factors of rats with diabetic nephropathy","volume":"13","author":"Guan","year":"2014","journal-title":"Genet Mol Res"},{"key":"2026020303245037000_jvim14839-bib-0022","first-page":"868A","article-title":"Beraprost sodium suppresses progression of chronic renal failure by protecting renal capillary endothelial cells and improving renal hypoxia in glomerulonephritis rats [Abstract]","volume":"24","author":"Yamaguchi","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2026020303245037000_jvim14839-bib-0023","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1054\/plef.2001.0315","article-title":"PGl2 analogue mitigates the progression rate of renal dysfunction improving renal blood flow without glomerular hyperfiltration in patients with chronic renal insufficiency","volume":"65","author":"Fujita","year":"2001","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"2026020303245037000_jvim14839-bib-0024","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0140-6736(68)90589-8","article-title":"Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis","volume":"2","author":"Risdon","year":"1968","journal-title":"Lancet"},{"key":"2026020303245037000_jvim14839-bib-0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0272-6386(12)80312-X","article-title":"Tubulointerstitial changes as a major determinant in the progression of renal damage","volume":"20","author":"Nath","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"2026020303245037000_jvim14839-bib-0026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-5198(19)43244-7","article-title":"The in vitro and ex vivo antiplatelet effect of TRK-100, a stable prostacyclin analog, in several species","volume":"47","author":"Nishio","year":"1988","journal-title":"Jpn J Pharmacol"},{"key":"2026020303245037000_jvim14839-bib-0027","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1476-5381.1986.tb11174.x","article-title":"Vasodilator actions of TRK-100, a new prostaglandin I2 analogue","volume":"89","author":"Akiba","year":"1986","journal-title":"Br J Pharmacol"},{"key":"2026020303245037000_jvim14839-bib-0028","first-page":"131","article-title":"Safety assessment of a prostacyclin derivative (beraprost sodium) in healthy cats","volume":"20","author":"Takenaka","year":"2011","journal-title":"J Anim Clin Med"},{"key":"2026020303245037000_jvim14839-bib-0029","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12882-015-0130-5","article-title":"Orally active prostacyclin analogue beraprost sodium in patients with chronic kidney disease: a randomized, double-blind, placebo-controlled, phase II dose finding trial","volume":"16","author":"Koyama","year":"2015","journal-title":"BMC Nephrol"},{"key":"2026020303245037000_jvim14839-bib-0030","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1939-1676.2011.00874.x","article-title":"Clinicopathological variables predicting progression of azotemia in cats with chronic kidney disease","volume":"26","author":"Chakrabarti","year":"2012","journal-title":"J Vet Intern Med"},{"key":"2026020303245037000_jvim14839-bib-0031","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/j.1939-1676.2006.tb02892.x","article-title":"Survival of cats with naturally occurring chronic renal failure is related to severity of proteinuria","volume":"20","author":"Syme","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020303245037000_jvim14839-bib-0032","first-page":"487","article-title":"Beraprost improves renal function and decreases uremic toxin in renal insufficiency","volume":"57","author":"Ohba","year":"2015","journal-title":"Nihon Jinzo Gakkai Shi"},{"key":"2026020303245037000_jvim14839-bib-0033","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/vec.12034","article-title":"Evidence-based step-wise approach to managing chronic kidney disease in dogs and cats","volume":"23","author":"Polzin","year":"2013","journal-title":"J Vet Emerg Crit Care (San Antonio)"},{"key":"2026020303245037000_jvim14839-bib-0034","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/j.1939-1676.2006.tb00702.x","article-title":"Tolerability and efficacy of benazepril in cats with chronic kidney disease","volume":"20","author":"King","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020303245037000_jvim14839-bib-0035","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1111\/jvim.13639","article-title":"Comparison of efficacy of long-term oral treatment with telmisartan and benazepril in cats with chronic kidney disease","volume":"29","author":"Sent","year":"2015","journal-title":"J Vet Intern Med"},{"key":"2026020303245037000_jvim14839-bib-0036","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1939-1676.2005.tb02713.x","article-title":"Assessment and management of proteinuria in dogs and cats: 2004 ACVIM Forum Consensus Statement (small animal)","volume":"19","author":"Lees","year":"2005","journal-title":"J Vet Intern Med"},{"key":"2026020303245037000_jvim14839-bib-0037","article-title":"IRIS treatment recommendations for CKD in cats","year":"2015"},{"key":"2026020303245037000_jvim14839-bib-0038","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1111\/jvim.13625","article-title":"Relationship between plasma fibroblast growth factor-23 concentration and survival time in cats with chronic kidney disease","volume":"29","author":"Geddes","year":"2015","journal-title":"J Vet Intern Med"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.14839","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/32\/1\/236\/66672662\/jvim14839.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/32\/1\/236\/66672662\/jvim14839.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T08:25:03Z","timestamp":1770107103000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/32\/1\/236\/8449690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,1]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.14839","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2018,1,1]]}}}